Table 4 Comparison of clinical characteristics between anti-MX1 autoantibody–positive and –negative patients with IIPs (n = 114) in cohort 2.
Variables | Anti-MX1 autoantibody | p value | |
|---|---|---|---|
Positive (n = 20) | Negative (n = 94) | ||
Age (years) | 75 (39–86) | 73 (33–86) | 0.72 |
Female, n (%) | 11 (55.0%) | 24 (25.5%) | 0.02* |
Smoking history (pack-year) | 15.75 (0–80) | 28.5 (0–135) | 0.33 |
ANA positive, n (%) | 0/19 (0.0%) | 10/91 (11.0%) | 0.21 |
RF positive, n (%) | 2/19 (10.5%) | 17/93 (18.3%) | 0.52 |
CK (U/L) | 72 (45–157) | 97 (28–976) | 0.14 |
CRP (mg/dL) | 0.12 (<0.04–1.1) | 0.09 (<0.04–1.66) | 0.96 |
KL-6 (U/mL) | 580 (310–2937) | 817.5 (99–4576) | 0.39 |
SP-D (ng/mL) | 220 (64.1–761) | 186 (19.8–1300) | 0.30 |
FVC (%) | 84.8 (44.9–107.6) | 79.9 (27.9–136.9) | 0.81 |
DLCO (%) | 45.4 (20.2–88.0) | 61.6 (4.2–147.5) | 0.05 |
Use of glucocorticoid, n (%) | 6 (30.0%) | 22 (23.4%) | 0.57 |
Use of pirfenidone, n (%) | 1 (5.0%) | 8 (8.5%) | 1.00 |
Diagnosis of IPF, n (%) | 4 (20.0%) | 15 (16.0%) | 0.74 |
HRCT findings | |||
Spared area (%) | 57.5 (38.3–93.3) | 65.8 (13.3–91.7) | 0.24 |
Predominantly lower, n (%) | 14 (70.0%) | 85 (90.4%) | 0.02* |
Predominantly peripheral, n (%) | 11 (55.0%) | 77 (81.9%) | 0.02* |
Predominantly peribronchovascular, n (%) | 9 (45.0%) | 42 (44.7%) | 1.00 |
Asymmetric distribution, n (%) | 0 (0.0%) | 3 (3.2%) | 1.00 |
GGA with traction bronchiectasis, n (%) | 19 (95.0%) | 81 (86.2%) | 0.46 |
GGA without traction bronchiectasis, n (%) | 17 (85.0%) | 72 (76.6%) | 0.56 |
Air-space consolidation, n (%) | 9 (45.0%) | 38 (40.4%) | 0.80 |
Honeycombing, n (%) | 6 (30.0%) | 34 (36.2%) | 0.80 |
Intralobular reticular opacity, n (%) | 16 (80.0%) | 73 (77.7%) | 1.00 |
Emphysema, n (%) | 7 (35.0%) | 35 (37.2%) | 1.00 |
Traction bronchiectasis, n (%) | 3 (15.0%) | 18 (19.2%) | 1.00 |
Sub pleural sparing, n (%) | 0 (0.0%) | 4 (4.3%) | 1.00 |
Upper lobe subpleural line, n (%) | 1 (5.0%) | 0 (0.0%) | 0.18 |
